Form 4: Insmed CFO Sara Bonstein Sells Shares Under 10b5-1 Trading Plan

Insmed's Chief Financial Officer, Sara Bonstein, executed sales of common stock on February 18, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• On February 18, 2025, Sara Bonstein, the Chief Financial Officer of Insmed Inc., sold shares of the company's common stock.
• The sales were executed under a pre-existing 10b5-1 trading plan.
• A total of 17,622 shares were sold at a weighted average price of $80.28, with prices ranging from $80.00 to $80.99 per share.
• An additional 700 shares were sold at a weighted average price of $81.00, with prices ranging from $81.00 to $81.01 per share.
• Following these transactions, Bonstein directly owns 118,863 shares of Insmed common stock.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing regarding stock sales by an executive under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment about the company's performance.

Industry Context

Executive stock sales are a common occurrence, and sales under 10b5-1 plans are generally viewed as less impactful since they are pre-arranged. Investors often monitor insider transactions for signals about a company's prospects, but pre-planned sales are less informative.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, but the pre-arranged nature of the sale mitigates concerns about insider information.

Key Dates